YON E Health

PUBLIC

Name	YON E Health (also branded YON E Global)
Tagline	Smart vaginal biosensor for pH, temperature, fertility, infection detection
Headquarters	Amsterdam, Netherlands
Founded	2022
Stage	Pre-Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	Hardware
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Pre-seed
Total Disclosed	€250,000 [TechFundingNews, 2024]

Links

PUBLIC

• Website: https://yone.global/
• LinkedIn: https://www.linkedin.com/in/roswitha-verwer-b2b636137/

Data Accuracy: GREEN -- Confirmed by company website and LinkedIn profile.

Executive Summary

PUBLIC YON E Health is an early-stage FemTech company seeking to commercialize a smart, at-home biosensor for vaginal health monitoring, a category where hardware innovation has historically faced significant regulatory and adoption hurdles [TechFundingNews, 2024]. Founded in 2022 by solo founder Roswitha Verwer, the company has secured a €250,000 pre-seed round to advance development of a device that aims to continuously track pH and basal body temperature, positioning it for both consumer fertility tracking and clinical infection detection [FemTech World, 2024]. The startup's initial differentiation appears twofold: a focus on a proprietary hardware sensor for continuous data, and an existing e-commerce operation (YON E Global) selling sustainable feminine care products, which may serve as an initial customer funnel and brand platform [FizzyMag, 2024].

Verwer, who is based between Amsterdam and Budapest, brings operational experience from a prior role as Chief Operating Officer at Affiliate Business Club, though the company has not publicly detailed additional technical or medical device leadership [Crunchbase Person Profile, 2026] [LinkedIn, 2026]. The pre-seed capital, led by PMK-Group with participation from UniPrisma Venture Studio and angel investor Matias Toye, is reportedly allocated for device development and preparatory clinical trials, though no product launch timeline or regulatory pathway has been disclosed [Silicon Canals, 2024]. Over the next 12-18 months, the critical milestones for investors to monitor will be the transition from concept to a functional prototype, the initiation of formal clinical validation studies, and the articulation of a clear regulatory strategy for the European and US markets.

Data Accuracy: YELLOW -- Core funding and product claims are reported by multiple trade publications, but key operational details and team composition lack independent verification.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	Hardware
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Pre-seed

Company Overview

PUBLIC

YON E Health was founded in 2022 in Amsterdam, with its operational and founder presence also noted in Budapest [LinkedIn, 2026]. The company's origin is tied to founder Roswitha Verwer's personal mission to address gaps in women's intimate health, a focus that emerged from her own experiences and a broader professional background in operations [Crunchbase Person Profile, 2026]. The venture appears to have launched with a dual-track strategy from the outset, pursuing both the development of a hardware biosensor and the operation of a direct-to-consumer e-commerce platform for sustainable feminine care products [FizzyMag, 2024].

The company's first significant external milestone was a €250,000 pre-seed funding round in 2024, led by PMK-Group with participation from UniPrisma Venture Studio and angel investor Matias Toye [TechFundingNews, 2024]. This capital was earmarked to advance the core biosensor technology toward clinical trials and manufacturing partnerships [FemTech World, 2024]. Public descriptions of the team emphasize a women-led, globally distributed structure, with contributors reportedly based in Amsterdam, Budapest, London, and several U.S. cities [GlobalWomanLeader, 2026].

Data Accuracy: YELLOW -- Core founding and funding facts are reported by multiple trade publications, but team composition and operational details are sourced primarily from company-affiliated channels.

Product and Technology

MIXED

The core proposition is a hardware-led approach to a sensitive, data-poor area of women's health. YON E Health is developing a smart vaginal biosensor designed for at-home monitoring of two key physiological markers: pH levels and basal body temperature [TechFundingNews, 2024] [FemTech World, 2024]. The device is intended to provide data for fertility tracking, infection risk detection, and insights into reproductive wellness and hormonal changes [Perplexity Sonar Pro Brief, 2024]. This positions the product as a potential tool for both consumer self-care and clinical use, aiming to fill a gap in continuous, quantitative monitoring of vaginal health.

Alongside the biosensor development, the company operates a separate commercial surface. YON E Health runs a FemCare e-commerce webshop under the YON E Global brand, which sells sustainable and organic intimate care products such as tampons [FizzyMag, 2024] [YON E Global, 2026]. The company describes this webshop as "Europe's newest sustainable FemCare webshop" and a "women-led safe haven" [FizzyMag, 2024]. The relationship between the hardware development and the e-commerce operation is not explicitly detailed in public sources, though the company presents both under a unified mission to empower women's health.

Public details on the biosensor's technical specifications, form factor, connectivity, or companion mobile app are limited. The pre-seed funding secured in 2024 is reported to be allocated toward device development, clinical trials, manufacturing partnerships, and mobile app refinement [Perplexity Sonar Pro Brief, 2024]. No live product deployments, named clinical partners, or regulatory clearances (e.g., CE mark, FDA) have been announced. The technology stack for the device and its associated software is not publicly disclosed.

Data Accuracy: YELLOW -- Product claims are consistent across multiple trade publications, but technical and development details are unverified. The e-commerce operation is confirmed via the company's own website.

Market Research and Opportunity

PUBLIC

The femtech market represents a persistent, data-poor frontier in healthcare where consumer demand for accessible, personalized insights is accelerating faster than traditional medical device development cycles. YON E Health is targeting a specific wedge within this broader category: continuous, at-home biosensing for vaginal and reproductive health metrics that have historically required episodic clinical visits or imprecise consumer-grade tools.

Third-party market sizing specific to vaginal biosensors is not publicly available in the cited sources. However, the broader femtech landscape provides context. The global femtech market was valued at approximately $51 billion in 2022 and is projected to grow to over $100 billion by 2030, according to a report from FemTech Analytics cited by multiple industry publications [FemTech World, 2024]. The fertility tech segment, a key adjacent market for YON E's proposed tracking capabilities, represents a multi-billion dollar subset of this total.

Several demand drivers underpin this growth. There is increasing consumer awareness and willingness to use technology for intimate health monitoring, a trend accelerated by the normalization of wearables for general wellness. Concurrently, there is a documented funding and research gap in women's health, creating commercial white space for startups. Regulatory pathways for digital health and wellness devices in Europe and the U.S. are also evolving, though they present a significant gating factor for medical-grade claims.

Key adjacent and substitute markets include the established ovulation prediction and fertility tracking app market (e.g., Clue, Flo), the broader wearable biosensor market for metrics like glucose and heart rate, and the direct-to-consumer sexual wellness and sustainable feminine care product space. The latter is notably where YON E currently operates its e-commerce webshop, providing an early, lower-friction touchpoint with its target audience while the hardware undergoes development [FizzyMag, 2024].

Femtech Market 2022 | 51 | $B
Femtech Market 2030 (projected) | 103 | $B

The projected near-doubling of the total addressable market for femtech by 2030 suggests strong macro tailwinds, but the specific success of a hardware biosensor will depend on clinical validation, user adoption, and clear differentiation from software-only fertility apps. The regulatory environment, particularly in the EU with its Medical Device Regulation (MDR), will be a critical factor in determining the timeline and capital required to bring a Class II medical device to market.

Data Accuracy: YELLOW -- Market sizing is cited from a third-party analyst report (FemTech Analytics) via secondary publications, but specific segmentation for the device category is not confirmed.

Competitive Landscape

MIXED

YON E Health operates at the intersection of two nascent but distinct markets, facing competition not from a single direct rival but from a fragmented set of incumbents and challengers across hardware, software, and consumer goods.

Given the absence of named, direct competitors in the structured sources, a formal comparison table cannot be constructed. The competitive analysis proceeds on a segment-by-segment basis.

• Hardware-centric fertility/health monitors. This is the most direct adjacent category, populated by wearable devices like the Oura Ring (temperature for readiness) and Ava bracelet (physiological signals for fertility). These are wrist-worn, non-invasive, and have established user bases and clinical validation. YON E's proposed vaginal biosensor represents a more invasive form factor targeting a specific, internal physiological environment (pH, localized temperature). The defensible edge, if proven, would be the specificity and continuous nature of the data stream from the vaginal canal, which wrist-worn devices cannot replicate. This edge is entirely perishable, however, contingent on successful device development, user comfort, and clinical proof. The company is most exposed here to the significant capital, brand, and distribution advantages of the established wearable players, who could develop or acquire similar internal sensing technology.

• At-home diagnostic test kits. Companies like Modern Fertility (now part of Ro) and Everlywell offer mail-order kits for hormone testing. These provide lab-analyzed, point-in-time snapshots rather than continuous monitoring. YON E's pitch of continuous data creates a different value proposition focused on trends and early detection. The competitive threat from this segment is their strong direct-to-consumer marketing engines and established regulatory pathways for diagnostic claims. YON E lacks this channel ownership and regulatory experience today.

• FemCare e-commerce platforms. The company's operational webshop for sustainable organic products [FizzyMag, 2024] places it in competition with a vast array of DTC brands like The Honey Pot Company, Cora, and mainstream retailers. This is a low-margin, high-competition space where defensibility typically comes from brand loyalty and supply chain control. YON E's edge here is unclear and likely not durable as a standalone business, though it could serve as a community-building and initial revenue channel to fund the core hardware development.

• Clinical and research-grade devices. The ultimate goal of a "clinical-grade" biosensor [StartupRise, 2024] would eventually pit YON E against medical device companies serving fertility clinics and gynecologists. This is a long-term, high-barrier channel the company does not currently own, requiring significant clinical trials and regulatory approvals (CE mark, FDA) that are not yet underway.

The most plausible 18-month competitive scenario hinges on execution in hardware development. If YON E can translate its pre-seed capital into a functional prototype and initiate a credible clinical validation study, it could carve out a defensible niche as a specialist in continuous vaginal bio-sensing, attracting a dedicated early adopter cohort. The "winner" in this case would be a company like Oura, which continues to deepen its fertility algorithms with less invasive data, if YON E fails to move beyond concept. The "loser" would be YON E itself if it cannot progress beyond the e-commerce shop, becoming another undifferentiated FemCare retailer while its hardware thesis stalls.

Data Accuracy: YELLOW -- Competitive mapping is inferred from category analysis; no direct competitors are named in public sources.

Opportunity

PUBLIC If YON E Health successfully commercializes its proposed biosensor, the opportunity lies in establishing a new, data-driven standard for at-home women's health monitoring, a category historically underserved by both consumer electronics and clinical diagnostics.

The headline opportunity is the creation of a category-defining, dual-purpose health platform. The company's device aims to combine continuous physiological monitoring for fertility with infection detection, a pairing not yet widely available in a single consumer-grade product. If the sensor achieves clinical validation and regulatory clearance, it could become the default tool for proactive vaginal health management, moving care from reactive doctor visits to preventative, at-home insight. The cited evidence that makes this outcome reachable, rather than purely aspirational, is the secured pre-seed funding specifically earmarked for advancing device development and clinical trials [TechFundingNews, 2024]. This capital provides a tangible runway to reach key technical and regulatory milestones, which are the primary gates to this opportunity.

Growth from an early-stage hardware project to a scaled health platform would likely follow one of several concrete paths. The scenarios below outline plausible, high-impact trajectories based on the company's stated focus areas and market dynamics.

Scenario	What happens	Catalyst	Why it's plausible
Clinical Partnership Lead	The biosensor is adopted as a remote monitoring tool by gynecologists and fertility clinics, creating a B2B2C sales channel.	A partnership with a European fertility clinic network for a pilot study, validating clinical utility.	The company's funding is directed toward trials [FemTech World, 2024], and the FemTech sector has precedent for clinical adoption of monitoring devices.
Direct-to-Consumer Ecosystem	The device becomes a flagship product, with the existing FemCare e-commerce site [FizzyMag, 2024] acting as a native distribution and cross-sell channel for consumables and data subscriptions.	A successful crowdfunding or pre-order campaign demonstrating initial consumer demand and funding initial production.	The company already operates a webshop, establishing a direct customer relationship and brand in women's wellness [FizzyMag, 2024].

Compounding success for YON E Health would be driven by a data network effect. Each device in use generates proprietary longitudinal health data specific to vaginal pH and basal body temperature. As the user base grows, this aggregated, anonymized dataset could improve the algorithm's predictive accuracy for fertility windows and infection risk, creating a product that becomes more valuable with scale. This data asset could also support future regulatory filings for new health claims or inform partnerships with pharmaceutical companies researching women's health conditions. While there is no public evidence this flywheel is yet in motion, the product's design is inherently oriented toward creating this type of moat.

The size of the win, should a scenario like the Clinical Partnership Lead play out, can be framed by looking at comparable exits in the digital health and FemTech hardware space. For example, the 2021 acquisition of fertility tracker Ava Women for over $100 million [Business Insider, 2021] provides a benchmark for a company that successfully bridged consumer hardware and clinical fertility data. In a scenario where YON E Health's device gains medical-grade validation and secures reimbursement codes in key European markets, achieving a similar outcome is conceivable. This represents a potential outcome, not a forecast, but it anchors the scale of the opportunity in a real-world transaction.

Data Accuracy: YELLOW -- The core opportunity thesis is built on the company's stated product roadmap and secured funding, which are publicly reported. The growth scenarios and comparables are analyst projections based on sector patterns, not yet evidenced by company-specific milestones.

Sources

PUBLIC

1. [TechFundingNews, 2024] YON E Health scoops €250K to reimagine vaginal health and fertility | https://techfundingnews.com/yon-e-health-vaginal-fertility-biosensors-funding/

2. [FemTech World, 2024] YON E Health raises €250k for its vaginal health device | https://www.femtechworld.co.uk/entrepreneur/yon-e-health-raises-e250k-for-its-vaginal-health-device-ftsu26/

3. [FizzyMag, 2024] Empowering Women's Health: An Interview with YON E Global | https://fizzymag.com/articles/yon-e-global-womens-health-interview

4. [Silicon Canals, 2024] Amsterdam's women-led femtech startup YON E Health secures funding | https://siliconcanals.com/yon-e-health-secures-funding/

5. [StartupRise, 2024] YON E Health Raises €250k To Develop Smart Vaginal Health Device | https://startuprise.co.uk/yon-e-health-raises-e250k-to-develop-smart-vaginal-health-device/

6. [Crunchbase Person Profile, 2026] Roswitha Verwer - Founder, CEO and CBO @ YON E Global - Crunchbase Person Profile | https://www.crunchbase.com/person/roswitha-verwer

7. [LinkedIn, 2026] Roswitha Verwer - YON E Health | LinkedIn | https://www.linkedin.com/in/roswitha-verwer-b2b636137/

8. [YON E Global, 2026] YON E Global's Selection of the Best Organic Tampons for Modern Women - YON E Global | https://yone.global/yon-e-globals-selection-of-the-best-organic-tampons-for-modern-women/

9. [GlobalWomanLeader, 2026] Dutch Femtech Startup YON E Health Raises 250K Euro | https://www.globalwomanleader.com/news/dutch-femtech-startup-yon-e-health-raises-250k-euro-nwid-5229.html

10. [Perplexity Sonar Pro Brief, 2024] YON E Health (also branded as YON E Global) is an Amsterdam-based FemTech startup | (Synthesized from multiple cited sources: TechFundingNews, FemTech World, FizzyMag, StartupRise, Silicon Canals)